Potential Predictive Factors for Response to Weekly Paclitaxel Treatment in Patients with Metastatic Breast Cancer

References

• Harris JR, Lippman ME, Morrow M, et al., eds. Diseases of the breast, 2 nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 749-798.
   Google Scholar
• Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med 1995; 332: 1004–1014.
   PubMed Web of Science ®Google Scholar
• Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treat-ment of metastatic reast cancer. J Clin Oncol 1998; 16: 3353-3361.
   Google Scholar
• Norton L. Evolving consepts in the systemic drug thera-py of breast cancer. Semin Oncol 1997; 24 (Suppl 10):S10.3-S10.10.
   Google Scholar
• Belotti D, Vergani V, Drudis T, et al. The microtubule-af fecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1943–1949.
   PubMed Web of Science ®Google Scholar
• Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitax-el. J Natl Cancer Inst 1996; 88: 1308–1314.
   PubMed Web of Science ®Google Scholar
• Asbury R, Chang A, Soros L, Asbury L, Rubins J. Weekly moderate-dose paclitaxel in advanced breast cancer. Semin Oncol 1999;26(Suppl 18):7.
   Google Scholar
• Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19: 4216–4223.
   PubMed Web of Science ®Google Scholar
• Waintraub SE, Cantwell S, DeVries J. Phase II study to evaluate the efficacy of weekly paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline +/- taxane +/- PSCT therapy. Proc Am Soc Clin Oncol 2000; 19: A470.
   Google Scholar
• Sikov W, Akerley W, Strenger R, et al. Weekly high-dose paclitaxel in locally advanced and metastatic breast can-cer: a BrUOG study. Semin Oncol 1999;26(Suppl 18):6.
   Google Scholar
• Mickiewicz E, Alvarez AM, Brosio C, et al. A promis-ing second-line treatment with weekly Taxol (T) in anthracy-dine recurrent advanced breast cancer (ABC) patients (pts). Proc Am Soc Clin Oncol 1999; 18(abstract 515).
   Google Scholar
• Breier S, Lebedinsky C, Ayaviri C, et al. Long-term weekly Taxol (paclitaxel) injection over 1-hour infusion: a phase II trial report. Breast Cancer Res Treat 1999; 57:124(abstract 523).
   Google Scholar
• Markman M, Hall JB, Spitz DL, Weiner S, Carson L, Van Le L, Baker ME. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002; 20: 2365–2369.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Kies M, Unger P, et al. Second-line weekly paclitaxel in patients with advanced non-small cell lung cancer failing first-line carboplatin/paclitaxel. Lung Cancer 2000;29(Suppl 1):6.
   Google Scholar
• Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immuno-histochemical analysis. Mod Pathol 1998; 11: 155–168.
   PubMed Web of Science ®Google Scholar
• Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999; 17: 3058–3063.
   Google Scholar
• Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966–978.
   Google Scholar
• Kobayashi S, Iwase H, Ito Y, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 1997; 42: 173–181.4.
   PubMed Web of Science ®Google Scholar
• Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Onc Hem 2002; 44: 53–13.
   Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182.
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expres-sion and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260, 1994.
   Google Scholar
• Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: rela-tionship with systemic treatment. Gene 159: 11, 1995.
   PubMed Web of Science ®Google Scholar
• Benz C, Sarup J, Scott G, et al. Estrogen- dependent, tamoxifen- resistant tumorigenic growth of MCF-7 cells trans-fected with Her2/neu. Breast Cancer Res Treat 24: 85, 1992.
   PubMed Web of Science ®Google Scholar
• Borg AK, Baldetorp B, Ferno M, et al. ERBB2 amplifi-cation is associated with tamoxifen resistance in steroid-recep-tor positive breast cancer. Cancer Lett 81: 137–144, 1994.
   PubMed Web of Science ®Google Scholar
• Aas T, Borresen AL, Geisler S, et al. Spesific P53 mutations are associated with de novo resistance to doxoru-bicin in breast cancer patients. Nat Med 1996; 2: 811–814.
   PubMed Web of Science ®Google Scholar
• Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-2512.
   Google Scholar
• Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and P53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50–56.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Bachhuber A, Victor A, et al. p53 expres-sion and resistance against paclitaxel in patients with metastat-ic breast cancer. J Cancer Res Clin Oncol 2003; 129 (5): 295–302.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Nat Cancer Inst 1990; 82: 1539–1545.
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic pri-mary tumour and axillary lymph node response to doxoru-bicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460–469.
   PubMed Web of Science ®Google Scholar
• Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cyto-toxic chemotherapy in metastatic breast cancer. N Engl J Med 1978; 298: 1223–1228.
   PubMed Web of Science ®Google Scholar
• Hietanen P, Blomqvist C, Wasenius V-M, Niskanen E, Franssila K, Nordling S. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 1995; 71: 1029-1032.
   Google Scholar
• Remvikos Y, Mosseri V, Zajdela A, et al. Prognostic value of the S-phase fraction of breast cancers treated by pri-mary radiotherapy or neoadjuvant chemotherapy. Ann NY Acad Sci 1993; 698: 193–203.
   PubMed Web of Science ®Google Scholar
• MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predivtive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiBl, p52 and CST it. Br J Cancer 1996; 74: 1458-1465.
   Google Scholar
• Sjostrom J, Blomqvist C, Heikkila P, et al. Predictive Value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000; 6: 3103-3110.
   Google Scholar
• Clark G, Sledge GWJ, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognos-tic factors in 1015 breast cancer patients. J Clin Oncol 1987; 5: 55–61.
   PubMed Web of Science ®Google Scholar
• Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56: 67–78.
   PubMed Web of Science ®Google Scholar
• Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast car-cinoma: importance of prognostic markers of the primary tumor. Cancer 2003; 97 (3): 545–53.
   PubMed Web of Science ®Google Scholar
• Efficace F, Biganzoli L, Piccart M, et al, EORTC-BCG-IDBBC-NDDG. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 2004; 40 (7): 1021–30.
   Google Scholar